Dicerna Pharmaceuticals Reaches Analyst Target Price
November 03, 2017 at 09:47 AM EDT
In recent trading, shares of Dicerna Pharmaceuticals Inc (DRNA) have crossed above the average analyst 12-month target price of $5.75, changing hands for $7.23/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..